


PRODUCT INFORMATION



Rucaparib

Item No. 15643

CAS Registry No.: 283173-50-2
Formal Name: 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one
Synonym: AG-014447
MF: C₁₉H₁₈FN₃O
FW: 323.4
Purity: ≥98%
UV/Vis.: λ_{max}: 209, 239, 274, 347, 356 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Rucaparib is supplied as a crystalline solid. A stock solution may be made by dissolving the rucaparib in the solvent of choice, which should be purged with an inert gas. Rucaparib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of rucaparib in these solvents is approximately 1, 25, and 30 mg/ml, respectively.

Rucaparib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, rucaparib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Rucaparib has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Rucaparib is a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor.¹ It reduces PARP1 activity in D283 Med medulloblastoma cells by 91.7% when used at a concentration of 1 μM. Rucaparib selectively inhibits the proliferation of MDA-MB-436 breast cancer cells expressing mutant *BRCA1* (IC₅₀s = 1.3 μM) over MCF-7 breast cancer cells expressing wild-type *BRCA1* and *BRCA2* (IC₅₀s = 20.2 μM).² It potentiates the growth inhibition induced by the DNA alkylating agent prodrug temozolomide (Item No. 14163) in D283 Med and D384 Med medulloblastoma cells when used at a concentration of 0.4 μM.¹ *In vivo*, rucaparib (1 mg/kg per day) potentiates temozolomide-induced delays in tumor growth in D283 Med and D384 Med mouse xenograft models. Formulations containing rucaparib have been used in the treatment of *BRCA* mutation-associated, drug-resistant ovarian, fallopian tube, or primary peritoneal cancers.

References

1. Daniel, R.A., Rozanska, A.L., Mulligan, E.A., *et al.* Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. *Br. J. Cancer* **103**(10), 1588-1596 (2010).
2. Drew, Y., Mulligan, E.A., Vong, W.T., *et al.* Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated *BRCA1* or *BRCA2*. *JNCI* **103**(4), 334-346 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/05/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM